Five Prime Therapeutics (NASDAQ:FPRX) was downgraded by BidaskClub from a “hold” rating to a “sell” rating in a research note issued to investors on Thursday.

FPRX has been the subject of several other research reports. Leerink Swann started coverage on Five Prime Therapeutics in a research report on Thursday, September 13th. They issued an “outperform” rating and a $24.00 price objective for the company. ValuEngine cut Five Prime Therapeutics from a “sell” rating to a “strong sell” rating in a research note on Saturday, July 28th. Wedbush boosted their target price on Five Prime Therapeutics from $17.00 to $19.00 and gave the company a “hold” rating in a research note on Friday, August 10th. Wells Fargo & Co reduced their target price on Five Prime Therapeutics from $58.00 to $35.00 and set an “outperform” rating on the stock in a research note on Thursday, August 9th. Finally, Citigroup reduced their target price on Five Prime Therapeutics from $60.00 to $44.00 and set a “buy” rating on the stock in a research note on Monday, August 20th. Two investment analysts have rated the stock with a sell rating, five have given a hold rating and five have issued a buy rating to the company. The stock presently has a consensus rating of “Hold” and a consensus price target of $29.67.

Shares of FPRX stock opened at $11.57 on Thursday. Five Prime Therapeutics has a fifty-two week low of $10.35 and a fifty-two week high of $30.25. The company has a market capitalization of $394.73 million, a price-to-earnings ratio of -2.15 and a beta of 3.23.

Five Prime Therapeutics (NASDAQ:FPRX) last announced its quarterly earnings data on Tuesday, November 6th. The biotechnology company reported ($1.37) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($1.15) by ($0.22). Five Prime Therapeutics had a negative net margin of 221.67% and a negative return on equity of 41.52%. The company had revenue of $5.77 million during the quarter, compared to the consensus estimate of $7.45 million. On average, equities research analysts forecast that Five Prime Therapeutics will post -4.04 EPS for the current fiscal year.

Several institutional investors and hedge funds have recently bought and sold shares of FPRX. Price Capital Management Inc. purchased a new position in shares of Five Prime Therapeutics during the third quarter valued at approximately $118,000. Xact Kapitalforvaltning AB purchased a new position in shares of Five Prime Therapeutics during the third quarter valued at approximately $145,000. Granite Investment Partners LLC purchased a new position in shares of Five Prime Therapeutics during the third quarter valued at approximately $240,000. MetLife Investment Advisors LLC increased its stake in shares of Five Prime Therapeutics by 48.7% during the second quarter. MetLife Investment Advisors LLC now owns 19,957 shares of the biotechnology company’s stock valued at $316,000 after buying an additional 6,535 shares during the period. Finally, Alambic Investment Management L.P. purchased a new position in shares of Five Prime Therapeutics during the second quarter valued at approximately $351,000. 86.40% of the stock is currently owned by hedge funds and other institutional investors.

Five Prime Therapeutics Company Profile

Five Prime Therapeutics, Inc, a clinical-stage biotechnology company, focuses on the discovery and development of immuno-oncology protein therapeutics. The company's product candidates include Cabiralizumab, an antibody that inhibits colony stimulating factor-1 receptor that is in Phase Ia/Ib clinical trials for the treatment of various cancers in combination with nivolumab; and is in Phase I/II clinical trials for the treatment of pigmented villonodular synovitis tumor.

Recommended Story: Calculate Your Return on Investment (ROI)

Analyst Recommendations for Five Prime Therapeutics (NASDAQ:FPRX)

Receive News & Ratings for Five Prime Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Five Prime Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.